|

Multiple Sclerosis Clinical Trials in Boston, MA

44 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPhase 3<1 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 3<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3<1 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPhase 3<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 4<1 mi
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsPhase 2<1 mi
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisPhase 3<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Phase 2<1 mi
Efgartigimod for the Treatment of Acute Optic NeuritisPhase 2<1 mi
Assessment of Synaptic Density in MSEarly 1<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/2<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Glucose Consumption in MS Using [F-18]FDG-PETPhase 4<1 mi
Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With HypertensionN/A<1 mi
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisPhase 4<1 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Phase 1<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 1<1 mi
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesPhase 1/2<1 mi
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsPhase 2<1 mi
Molecular Imaging of NET Using [C-11]MRB-PET in MSPhase 1/2<1 mi
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALSPhase 1<1 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyPhase 2<1 mi
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis—<1 mi
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple SclerosisPhase 2<1 mi
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability StudyN/A<1 mi
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition—<1 mi
Care in Multiple Sclerosis (MS)—<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisPhase 2<1 mi
Genes and Environment in Multiple Sclerosis—<1 mi
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis SubjectsPhase 1<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2<1 mi
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple SclerosisPhase 44 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease—9 mi
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis—9 mi
Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisN/A9 mi
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives—9 mi
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)—23 mi
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityPhase 223 mi
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisPhase 139 mi
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple SclerosisPhase 139 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Phase 339 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.